For these reasons, reduction of LDL-C concentration is the main (primary) target of lipid-lowering therapy
What you build on that foundation determines whether you track with the trial averages, exceed them, or fall below
Peptides in this category act on these different stages: BPC-157 stimulates angiogenesis and tendon healing, TB-500 (Thymosin Beta-4) regulates actin and reduces fibrosis, ARA-290 targets neuroprotection via the EPO-R/CD131 receptor, and VIP modulates inflammation via the VPAC1/VPAC2 receptors
Weight loss and bone mineral density
Using #TargetTrialEmulation across 703 clinical practices, we examined over 23,000 patients aged 45+ from 20192024 - we found Semaglutide was associated with a lower risk of @MACE (primarily driven by stroke) compared to empagliflozin Dulaglutide and empagliflozin had similar cardiovascular outcomes Hypothesis generating signal of semaglutide's more profound effect in 65 years and younger patients which needs to be looked at in future studies
